Printer Friendly

Annual zoledronic acid dose reduces back pain disability.

Washington -- A yearly dose of zoledronic acid significantly reduced the number of days of disability because of back pain in older women with osteoporotic fractures, based on data from the HORIZON Pivotal Fracture study.

"Osteoporotic fractures can result in back pain, significant disability, reduced quality of life, and death," Jane A. Cauley, Dr.P.H., of the University of Pittsburgh, and her colleagues wrote in a poster presented at the annual meeting of the American Geriatrics Society.

One in three women aged 50 years and older will suffer an osteoporotic fracture, they noted. In the HORIZON Pivotal Fracture Study, a randomized, controlled trial of more than 7,000 postmenopausal women aged 65-79 years, a yearly dose of 5 mg zoledronic acid significantly reduced all types of clinical fractures, compared with placebo. The medication was administered in a 15-minute intravenous infusion.

In the current study, funded by Novartis Pharma AG in Basel, Switzerland, the researchers went a step further and compared the effect of the yearly dose of zoledronic acid on the number of days of disability, bed rest, and back pain. The intent-to-treat population included 3,875 women who received zoledronic acid and 3,861 who received a placebo. The researchers collected information on days of limited activity and days of bed rest because of an osteoporotic fracture or back pain every 3 months during a 3-year period.

Older age and a prevalent vertebral fracture were significantly associated with more days of bed rest, back pain, and fracture-related disability.

Overall, women who took zoledronic acid averaged significantly fewer bed rest days because of fracture, compared with those in the placebo group (1.6 vs. 2.2 days, respectively) and significantly fewer limited-activity days because of fracture, compared with the placebo group (5.9 vs. 9.9 days).

Similarly, the women who took zoledronic acid averaged significantly fewer bed rest days because of back pain, compared with those in the placebo group (8.2 vs. 9.2 days, respectively) and significantly fewer limited-activity days because of back pain, compared with the placebo group (60.5 vs. 71.9 days).

After the investigators controlled for incident clinical fracture, zoledronic acid remained significantly associated with fewer days of limited activity from back pain.
Limited-Activity Days Because of Back Pain in Women With
Osteoporotic Fractures

Zoledronic acid (n = 3,875) 60.5 days
Placebo (n - 3,861) 71.9 days

Note: Based on a 3-year study of women aged 65-79 years.

Source: Dr. Cauley

Note: Table made from bar graph.


BY HEIDI SPLETE

Senior Writer
COPYRIGHT 2008 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Endocrinology
Author:Splete, Heidi
Publication:Internal Medicine News
Article Type:Clinical report
Geographic Code:1USA
Date:Nov 1, 2008
Words:421
Previous Article:ACP guidelines address osteoporosis therapy.
Next Article:Suicide risk 15 times higher for PTSD patients.
Topics:


Related Articles
Prostate Ca: annual zoledronic acid protects bone; Prostate cancer patients taking androgen-deprivation therapy had higher BMD after the Zometa...
Zoledronic acid zaps bone loss in breast cancer.
Zoledronic acid after hip fracture.
Zoledronic acid cuts risk of breast ca relapses.
Zoledronic acid an option for osteoporotic men.
Zoledronic acid slows bone loss in osteopenia.
Zoledronic acid tops raloxifene for bone loss.
Biyearly zoledronic acid gets nod for bone loss prevention.
Steroids for lumbar radiculopathy.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters